Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Equity Average (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Equity Average for 7 consecutive years, with $9.1 million as the latest value for Q3 2025.

  • For Q3 2025, Equity Average rose 6.64% year-over-year to $9.1 million; the TTM value through Sep 2025 reached $9.1 million, up 6.64%, while the annual FY2024 figure was $10.1 million, 7.37% down from the prior year.
  • Equity Average hit $9.1 million in Q3 2025 for Cyclerion Therapeutics, up from $8.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $60.8 million in Q3 2021 and bottomed at $4.5 million in Q2 2023.
  • Average Equity Average over 5 years is $22.6 million, with a median of $10.6 million recorded in 2024.
  • Year-over-year, Equity Average tumbled 85.46% in 2023 and then skyrocketed 106.13% in 2024.
  • Cyclerion Therapeutics' Equity Average stood at $52.3 million in 2021, then tumbled by 74.22% to $13.5 million in 2022, then dropped by 10.44% to $12.1 million in 2023, then fell by 29.44% to $8.5 million in 2024, then rose by 6.22% to $9.1 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $9.1 million, $8.7 million, and $8.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.